Current Value
$547.751 Year Return
Current Value
$547.751 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 64.57% | $5.26B | 0.45% |
BBH | 63.11% | $330.62M | 0.35% |
FBT | 58.86% | $1.01B | 0.54% |
PBE | 57.36% | $223.19M | 0.58% |
XBI | 54.67% | $4.82B | 0.35% |
RSPH | 52.50% | $729.81M | 0.4% |
VHT | 51.97% | $15.35B | 0.09% |
FHLC | 51.54% | $2.44B | 0.084% |
HYXF | 51.52% | $182.12M | 0.35% |
PINK | 51.37% | $130.57M | 0.5% |
IYH | 51.36% | $2.73B | 0.39% |
FXH | 50.23% | $903.07M | 0.62% |
XLV | 50.12% | $34.28B | 0.09% |
PPH | 49.43% | $610.46M | 0.36% |
IHE | 48.99% | $550.45M | 0.39% |
IXJ | 48.69% | $3.75B | 0.41% |
XPH | 48.18% | $147.96M | 0.35% |
GNOM | 46.15% | $44.57M | 0.5% |
MOAT | 45.93% | $12.66B | 0.47% |
NOBL | 43.29% | $11.37B | 0.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMNN | 0.09% | $16.26M | -34.16% | 0.00% |
KR | -0.09% | $46.43B | +38.38% | 1.85% |
UNH | 0.11% | $279.00B | -37.22% | 2.74% |
LEU | -0.12% | $3.01B | +317.85% | 0.00% |
LNG | -0.12% | $53.29B | +38.03% | 0.81% |
PINC | -0.14% | $1.79B | +18.29% | 3.85% |
EVGO | -0.15% | $470.93M | +38.74% | 0.00% |
GEO | 0.34% | $3.48B | +64.31% | 0.00% |
OXBR | 0.42% | $16.90M | +1.79% | 0.00% |
IBEX | -0.42% | $400.37M | +89.02% | 0.00% |
AU | 0.48% | $23.49B | +78.98% | 2.23% |
FARO | 0.49% | $848.40M | +170.44% | 0.00% |
MYRG | 0.50% | $2.85B | +35.33% | 0.00% |
LFWD | 0.51% | $10.50M | -81.82% | 0.00% |
KGC | -0.53% | $19.10B | +87.82% | 0.77% |
VHC | -0.53% | $48.19M | +108.24% | 0.00% |
PHYS.U | -0.54% | - | - | 0.00% |
HIMS | 0.58% | $10.62B | +131.63% | 0.00% |
AVD | 0.62% | $140.05M | -52.08% | 0.00% |
EGO | 0.69% | $4.26B | +33.87% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RRGB | -25.69% | $122.20M | +4.87% | 0.00% |
UUU | -18.08% | $7.17M | +101.30% | 0.00% |
ROOT | -11.21% | $1.99B | +127.12% | 0.00% |
MO | -8.25% | $99.67B | +28.77% | 6.90% |
CARV | -6.67% | $8.88M | +26.23% | 0.00% |
MKTX | -6.55% | $8.22B | +9.03% | 1.38% |
PULM | -6.53% | $25.57M | +219.63% | 0.00% |
NEXT | -5.76% | $2.33B | +11.89% | 0.00% |
RLX | -5.14% | $2.13B | +27.17% | 0.42% |
TZOO | -4.73% | $146.68M | +75.10% | 0.00% |
ATEC | -4.68% | $1.60B | +9.82% | 0.00% |
UVV | -4.43% | $1.44B | +22.56% | 5.57% |
NGVC | -4.06% | $909.29M | +82.08% | 1.16% |
USM | -4.04% | $5.41B | +13.33% | 0.00% |
AIFU | -4.02% | $6.79B | +102.19% | 0.00% |
OR | -3.85% | $4.80B | +61.45% | 0.75% |
SFM | -3.71% | $15.65B | +93.49% | 0.00% |
STG | -3.61% | $30.78M | -22.51% | 0.00% |
LRN | -3.60% | $5.99B | +100.06% | 0.00% |
TDS | -3.45% | $4.06B | +75.12% | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -29.14% | $164.54M | 0.85% |
TAIL | -26.82% | $99.63M | 0.59% |
BTAL | -21.31% | $296.22M | 1.43% |
IVOL | -15.28% | $347.03M | 1.02% |
XHLF | -13.48% | $1.73B | 0.03% |
CLIP | -11.90% | $1.51B | 0.07% |
BIL | -11.39% | $42.24B | 0.1356% |
TBLL | -11.37% | $2.13B | 0.08% |
XONE | -9.94% | $625.28M | 0.03% |
TPMN | -9.32% | $30.70M | 0.65% |
GBIL | -8.92% | $6.37B | 0.12% |
BILZ | -8.11% | $821.74M | 0.14% |
BOXX | -7.93% | $6.80B | 0.19% |
AGZD | -7.04% | $102.70M | 0.23% |
JMST | -6.42% | $4.06B | 0.18% |
FXY | -5.66% | $816.38M | 0.4% |
BILS | -5.18% | $3.81B | 0.1356% |
SPTS | -4.82% | $5.80B | 0.03% |
ULST | -3.46% | $654.75M | 0.2% |
FMF | -3.28% | $158.70M | 0.95% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BIIB | 53.33% | $19.52B | -40.70% | 0.00% |
MTD | 45.97% | $25.06B | -10.96% | 0.00% |
SNY | 45.76% | $120.14B | +0.92% | 4.51% |
RVTY | 45.40% | $11.89B | -1.62% | 0.28% |
IQV | 44.29% | $28.48B | -20.39% | 0.00% |
COO | 42.33% | $14.57B | -14.61% | 0.00% |
ROIV | 42.28% | $7.46B | +4.68% | 0.00% |
LYB | 41.94% | $20.11B | -34.27% | 8.60% |
A | 41.55% | $34.28B | -4.34% | 1.00% |
PFE | 41.47% | $143.95B | -8.59% | 6.72% |
LFUS | 41.37% | $5.87B | -6.00% | 1.17% |
GEHC | 41.24% | $34.85B | -1.45% | 0.17% |
KRYS | 40.98% | $4.08B | -20.39% | 0.00% |
APTV | 40.94% | $15.72B | +3.44% | 0.00% |
BRKR | 40.89% | $6.43B | -31.33% | 0.47% |
VRTX | 40.79% | $117.36B | -2.82% | 0.00% |
ARW | 40.75% | $6.84B | +10.34% | 0.00% |
TMO | 40.66% | $161.48B | -20.14% | 0.38% |
XYL | 40.51% | $32.05B | -0.75% | 1.15% |
MFA | 40.51% | $996.76M | -7.87% | 14.52% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TFLO | -0.08% | $6.82B | 0.15% |
STOT | 0.08% | $254.07M | 0.45% |
IAU | 0.10% | $46.70B | 0.25% |
OILK | -0.12% | $71.87M | 0.69% |
CTA | -0.14% | $1.06B | 0.76% |
BAR | 0.16% | $1.11B | 0.1749% |
CANE | 0.28% | $10.37M | 0.29% |
UGA | 0.28% | $72.33M | 0.97% |
AAAU | 0.32% | $1.54B | 0.18% |
SGOL | 0.34% | $5.17B | 0.17% |
USFR | -0.38% | $18.56B | 0.15% |
GLD | 0.41% | $100.19B | 0.4% |
UUP | -0.43% | $201.63M | 0.77% |
DBE | 0.45% | $52.20M | 0.77% |
CMBS | 0.52% | $449.66M | 0.25% |
OUNZ | 0.62% | $1.73B | 0.25% |
KCCA | -0.65% | $109.43M | 0.87% |
VTIP | -0.76% | $15.33B | 0.03% |
SMB | -0.76% | $274.97M | 0.07% |
GLDM | -0.84% | $15.74B | 0.1% |
Yahoo
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
Yahoo
Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.
Finnhub
TARRYTOWN - Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic to treat adult patients with relapsed or refractory ...
Yahoo
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this […]
Yahoo
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
Yahoo
Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1 trial; results reported were among the highest overall (70%) and complete response rates (45%) for bispecific antibodies in heavily pre-treated multiple myeloma patients Lynozyfic provides a patient-centric response-adapted dosing regimenTARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharma
Double maintains 9 strategies that include REGN - Regeneron Pharmaceuticals, Inc.